A5354/EARLIER: Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection . . . Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses

Study Location:

Washington

Topic:

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02859558?term=ACTG+5354&rank=1

Coordinator:

Anna Wimpleberg

Enrollment:

Open

Trial Period:

Ongoing

This study will include people who have very recently been infected with HIV and will start anti-HIV (antiretroviral) drugs right away to see how this may change HIV’s impact on the body. 

This study is trying to find out if starting antiretroviral drugs very early in HIV infection will change the following:

  • Limit the virus from getting into hidden areas of the body (“reservoirs”).
  • Change how the immune system helps to control the virus.

Men and women who:

  • Are at least 18 years old
  • Have had certain lab tests done that confirm very early HIV infection
  • Are willing to take antiretroviral drugs right away to treat HIV.

Categories

Location
Topic

Clinical Trials

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

HPTN 078: Enhancing Recruitment, Linkage to Care and...

The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More